Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies by Dirix, Luc et al.
Clinical Therapeutics/Volume ], Number ], 2016Effect of Itraconazole and Rifampin on the
Pharmacokinetics of Olaparib in Patients With
Advanced Solid Tumors: Results of Two Phase I
Open-Label StudiesLuc Dirix, MD, PhD1; Helen Swaisland2,*; Henk M.W. Verheul, MD, PhD3;
Sylvie Rottey, MD, PhD4; Karin Leunen, MD5; Guy Jerusalem, MD, PhD6;
Christian Rolfo, MD, PhD7; Dorte Nielsen, MD, DMSc8;
L. Rhoda Molife, BMedSci, BM BS, MRCP, MD, MSc9;
Rebecca Kristeleit, BSc, MRCP, PhD10; Judith de Vos-Geelen, MD, PhD11;
Morten Mau-Sørensen, MD, PhD12; Patricia Soetekouw, MD11;
Carla van Herpen, MD, PhD13; Anitra Fielding, MBChB2; Karen So, MBBS, MRCS, MD14;
Wendy Bannister15; and Ruth Plummer, MD, D.Phil, FRCP16
1Medical Oncology, Sint-Augustinus-University of Antwerp, Antwerp, Belgium; 2AstraZeneca, Macclesfield,
United Kingdom; 3Department of Medical Oncology, VU Medisch Centrum, Amsterdam, the Netherlands;
4Department of Medical Oncology, Ghent University Hospital and Heymans Institute of Pharmacology,
Ghent, Belgium; 5Universitair Ziekenhuizen Leuven, Leuven, Belgium; 6CHU Sart-Tilman and Liege
University, Liege, Belgium; 7Oncology Department, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium;
8Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark; 9The Royal Marsden and
Institute of Cancer Research, Sutton, United Kingdom; 10University College London Cancer Institute,
London, United Kingdom; 11Division of Medical Oncology, Maastricht University Medical Center,
Maastricht, the Netherlands; 12Department of Oncology, University Hospital, Rigshospitalet, Copenhagen,
Denmark; 13Radboud University Medical Center, Nijmegen, the Netherlands; 14AstraZeneca, Cambridge,
United Kingdom; 15PHASTAR, London, United Kingdom; and 16Northern Centre for Cancer Care,
Newcastle upon Tyne, United KingdomAccepted for publication August 23, 2016.ABSTRACT
Purpose: The metabolism of olaparib, a potent
inhibitor of poly(ADP-ribose) polymerase (PARP)
with demonstrated efﬁcacy in patients with BRCA-
mutated ovarian cancer, is mediated by cytochrome
P450 (CYP) enzymes (predominantly CYP3A4/5). We
assessed the potential of a CYP3A4 inhibitor (itraco-
nazole) and inducer (rifampin) to alter the pharmaco-
kinetic (PK) proﬁle of olaparib following single oral
tablet doses.
Methods: Two Phase I, open-label, non-random-
ized trials were conducted in patients with advanced
solid tumors. In Study 7, patients received olaparib
alone and co-administered with itraconazole; in Study*Current afﬁliation: Therakin Consulting, Sandbach, United
Kingdom.
] 20168, a separate group of patients received olaparib alone
and co-administered with rifampin. No interaction
between itraconazole and olaparib was concluded if
two-sided 90% CIs for the treatment ratios of AUC
and/or AUC0–t and Cmax fell within the bioequivalence
range of 0.80–1.25. An interaction between rifampin
and olaparib was concluded if the lower limit of the
90% CI for the treatment ratios waso0.5 (ie,450%
decrease in olaparib AUC or Cmax in the presence of
rifampin compared with olaparib alone).
Findings: In Study 7 (N ¼ 59; 17 male, 42 female),
56 and 53 patients were evaluable for PK analysishttp://dx.doi.org/10.1016/j.clinthera.2016.08.010
0149-2918/$ - see front matter
& 2016 Elsevier HS Journals, Inc. All rights reserved.
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Clinical Therapeuticsfollowing treatment with olaparib alone and olaparib
plus itraconazole, respectively; in Study 8 (N ¼ 22; 4
male, 18 female), all patients were evaluable. Co-
administration of olaparib with itraconazole resulted
in a statistically signiﬁcant increase in the relative
bioavailability of olaparib: Cmax treatment ratio, 1.42
(90% CI, 1.33–1.52); mean AUC treatment ratio,
2.70 (90% CI, 2.44–2.97). Mean CL/F and Vz/F were
reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L),
although mean t½ was unchanged (15.0 vs 15.6
hours). Co-administration of olaparib with rifampin
resulted in a statistically signiﬁcant decrease in the
relative bioavailability of olaparib: Cmax treatment
ratio, 0.29 (90% CI, 0.24–0.33); mean AUC treat-
ment ratio, 0.13 (90% CI, 0.11–0.16). CL/F and Vz/F
were increased when olaparib and rifampin were co-
administered (6.36 vs 48.3 L/h and 112 vs 1076 L);
however, mean t½ was unchanged (13.0 vs 15.8
hours). Safety data for olaparib following tablet
dosing were consistent with the known safety proﬁle.
Implications: Exposure to olaparib was signiﬁ-
cantly increased when co-administered with the potent
CYP3A4 inhibitor itraconazole, and signiﬁcantly de-
creased when co-administered with the potent
CYP3A4 inducer rifampin, compared with olaparib
alone. Potent CYP3A4 enzyme inhibitors and inducers
should be avoided during olaparib treatment.
ClinicalTrials.gov identiﬁers: NCT01900028 (Study 7)
and NCT01929603 (Study 8). (Clin Ther. 2016;]:]]]–
]]]) & 2016 Elsevier HS Journals, Inc. All rights
reserved.
Key words: CYP3A4, itraconazole, olaparib, phar-
macokinetic, rifampin.INTRODUCTION
Olaparib* is a potent, oral poly(ADP-ribose)
polymerase (PARP) inhibitor that blocks base-
excision repair of single-strand DNA breaks (SSBs)
by trapping PARP at sites of DNA damage.1 PARP
inhibitors also impair, via other mechanisms, high-
ﬁdelity repair of double-strand DNA breaks in tumor
cells with deﬁciencies in homologous recombination repair
(HRR), such as BRCA1/2 mutations (BRCA1/2m).2,3
The prevention of SSB repair as a result of PARP
inhibition in tumor cells with HRR deﬁciencies leads*Trademark: Lynparza™ (AstraZeneca, Cambridge, United
Kingdom).
2to irreparable double-strand breaks being formed that
result in tumor cell death by PARP-inhibitor-induced
synthetic lethality.4 PARP inhibitors can also induce
lethality in tumor cells that have deﬁciencies in DNA
damage repair mechanisms other than HRR
deﬁciencies.
On 19 December, 2014, olaparib (capsule formu-
lation) became the ﬁrst PARP inhibitor approved for
treatment when the United States Food and Drug
Administration (FDA) granted accelerated approval of
olaparib for the monotherapy treatment of patients
with relapsed germline BRCA mutation (gBRCAm)
ovarian cancer who have received three or more lines
of chemotherapy.5 In the same week, the European
Medicines Agency (EMA) granted approval of
olaparib as monotherapy maintenance treatment of
adult patients with platinum-sensitive, relapsed
BRCAm (germline and/or somatic) ovarian cancer
who are in complete or partial response to platinum-
based chemotherapy based on Study 19
(D0810C00019; NCT00753545) data.6 In patients
with platinum-sensitive, recurrent serous ovarian
cancer, maintenance monotherapy with a capsule
formulation of olaparib 400 mg twice
daily (bid) signiﬁcantly prolonged progression-free
survival (PFS) versus placebo.7 A prespeciﬁed
retrospective analysis of this patient populat-
ion showed that patients with a BRCAm
receive greater treatment beneﬁt.8 In Study 42
(D0810C00042; NCT01078662), which involved
patients with a germline BRCA1/2m and solid
tumors refractory to standard therapy, treatment
with a capsule formulation of olaparib 400 mg bid
prolonged tumor responses across a spectrum of
malignancies, including ovarian, breast, pancreatic,
and prostate cancers.9 To receive the recommended
400 mg bid dose of olaparib, patients are required to
take 16  50 mg large capsules per day and,
consequently, patient compliance may be compro-
mised. A tablet formulation has therefore been
developed to deliver a therapeutic dose in fewer
and smaller units. A recommended tablet dose of
300 mg bid has been determined in a Phase I trial
(Study 24, D0810C00024; NCT00777582) for ad-
ministration in Phase III studies.10
In vitro data have shown that the metabolism of
olaparib is mediated by cytochrome P450 (CYP) enzymes
(predominantly CYP3A4/5); co-administration with po-
tent inhibitors or inducers of CYP3A4 would therefore beVolume ] Number ]
L. Dirix et al.expected to alter the pharmacokinetics (PK) of olaparib
(McCormick & Swaisland, manuscript in preparation for
submission). Since patients receiving olaparib are likely to
be taking multiple medications, signiﬁcant PK drug–drug
interactions could lead to alterations in plasma concen-
trations of olaparib, potentially resulting in a reduction in
efﬁcacy or an increase in drug-related toxicity.
The results of two clinical studies, which inves-
tigated the potential for PK interactions between
either olaparib (tablet formulation) and itraconazole,
an antifungal agent and potent CYP3A4 inhibitor
(Study 7), or olaparib and rifampin, a bactericidal
antibiotic and potent CYP3A4 inducer (Study 8), are
reported.PATIENTS AND METHODS
Study Design
Both studies were Phase I, open-label, non-random-
ized, multicenter trials in patients with advanced solid
tumors (Study 7, NCT01900028 [D0816C00007];
Study 8, NCT01929603 [D0816C00008]). Study 7
consisted of 3 parts (A, B, and C), and Study 8
comprised 2 parts (A and B) (Figure 1).
In both studies, Part A assessed the effect of either
the CYP3A4 inhibitor (Study 7) or CYP3A4 inducer
(Study 8) on the PK proﬁle of olaparib following
single dosing of the tablet formulation, and only dataPart A
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Figure 1. Study designs. *Open-label study designed to
following multiple oral dosing of olaparib tab
2016 Aug 23. [Epub ahead of print]); †Lon
(Study 7) or Part B (Study 8) continued access
(data to be reported separately)
] 2016from this part of each study are reported in this
manuscript. Data from Study 7, Part B (assessment of
the effect of olaparib on the QT interval following
multiple oral dosing of olaparib tablets) and Part C
(long-term safety), and from Study 8, Part B (long-
term safety), will be reported separately.
In Study 7, Part A consisted of a non-randomized,
open-label, sequential, two-treatment design. Patients
received a single oral dose of olaparib 100 mg (1 
100 mg tablet) on day 1 after a 10-hour fast, and a
single oral dose of olaparib 100 mg (1  100 mg
tablet) administered concurrently with itraconazole
200 mg (2  100 mg tablets) on day 9 after an
overnight fast. Itraconazole 200 mg was administered
once daily on days 5–11 with a full meal (except for
the dose on day 9).
In Study 8, Part A also consisted of a non-
randomized, open-label, sequential, two-treatment
design. Patients received a single oral dose of olaparib
300 mg (2  150 mg tablets) on day 1, and a single
oral dose of olaparib 300 mg (2  150 mg tablets)
administered concurrently with rifampin 600 mg (2 
300 mg tablets) on day 14. The treatments on days 1
and 14 were administered following an overnight fast,
and patients remained fasting for 2 hours post-dose.
Rifampin 600 mg (2  300 mg tablets) was adminis-
tered once daily following an overnight fast on days
5–17.uential
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g-term safety study allowed patients from Part A
to olaparib tablets to provide additional safety data
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In both studies, eligible patients were aged Z18
years and had a conﬁrmed (histologically or, where
appropriate, cytologically) malignant solid tumor
refractory or resistant to standard therapy and for
which no suitable standard therapy exists. Patients
also needed to have a life expectancy of Z16 weeks,
an Eastern Cooperative Oncology Group (ECOG)
performance statusr2, and adequate organ and bone
marrow function measured within 28 days prior to
administration of olaparib. Patients were excluded if
they had recently received or were receiving medica-
tions known to be inhibitors or inducers of CYP3A4.
Additionally, any intake of grapefruit or Seville
oranges, or products containing these components,
was not permitted within 7 days prior to olaparib
dosing. Patients were required to be on a stable
concomitant medication regimen, deﬁned as no
changes in medication or dose within 2 weeks prior
to olaparib dosing, except for bisphosphonates, deno-
sumab and corticosteroids, which needed to be stable
for at least 4 weeks prior to the start of olaparib
dosing.
The institutional review boards or independent
ethics committees of all investigational sites approved
both protocols, and the studies were performed in
accordance with the Declaration of Helsinki, Good
Clinical Practice, and the AstraZeneca Policy on
Bioethics.11 All patients provided written informed
consent.
Study Objectives
Primary and secondary objectives were: to inves-
tigate the effect of itraconazole (Study 7) or rifampin
(Study 8) on the PK proﬁle of olaparib following oral
dosing of the tablet formulation in patients with
advanced solid tumors; to demonstrate exposure to
itraconazole and its metabolite hydroxyitraconazole
(Study 7); to demonstrate exposure to rifampin and
induction of CYP by rifampin (assessed by determin-
ing plasma concentrations of 4β-hydroxycholesterol, a
biomarker for CYP3A4 activity)12,13 (Study 8); and to
further investigate the safety and tolerability of ola-
parib tablets in patients with advanced solid tumors
(both studies).
Pharmacokinetic Assessment
Blood samples for determination of olaparib con-
centrations were taken on days 1 and 9 for Study 7,4and on days 1 and 14 for Study 8, as follows:
pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12,
24, 48 and 72 hours post-dose.
Blood samples for determination of itraconazole
and hydroxyitraconazole concentrations were taken
on day 9, pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12
and 24 hours post-dose. Blood samples for determi-
nation of rifampin concentrations were taken on days
5, 9, 14 and 17 at 2 hours post-dose, and blood
samples for determination of 4β-hydroxycholesterol
were taken on days 5, 9, 14 and 17 prior to
administration of rifampin.
The determination of drug concentrations (ola-
parib, itraconazole/metabolite, rifampin) and the PK
analyses of these concentrations were conducted by
Covance Laboratories in Harrogate, United Kingdom
and Alnwick, United Kingdom, respectively;14 The
lower limit of quantiﬁcation for the olaparib,
itraconazole/metabolite, and rifampin assays were
0.5, 2 and 50 ng/mL, respectively. Analyses of 4β-
hydroxycholesterol were conducted by PRA Interna-
tional, Assen, the Netherlands.15 PK parameters were
determined using standard, non-compartmental
analysis: maximum plasma concentration (Cmax),
area under the plasma concentration–time curve
(AUC) from time zero (pre-dose) to inﬁnity, AUC
from time zero to time of last quantiﬁable sample
(AUC0–t), time to maximum plasma concentration
(tmax), terminal half-life (t½), apparent clearance
(CL/F) and apparent volume of distribution (Vz/F).
PK parameters determined for itraconazole included
Cmax, AUC over the dosing interval AUCtau, tmax, and
CL/F; for hydroxyitraconazole, included Cmax,
AUCtau, and tmax. PK computations were performed
using PhoenixTM for WinNonlin (Certara USA, Inc,
Princeton, New Jersey). Plasma concentrations of
rifampin and 4β-hydroxycholesterol were summarized.
Patients were monitored for adverse events (AEs)
throughout both studies. AEs were graded according to
the National Cancer Institute Common Terminology
Criteria (NCI-CTC) version 4. All serious AEs (SAEs)
and AEs related to treatment were followed up to
resolution. For both studies, AEs were summarized
separately for the olaparib alone and olaparib plus
itraconazole/rifampin dosing periods. For the olaparib
plus itraconazole/rifampin dosing period, only new AEs
occurring from the ﬁrst dose of olaparib plus itracona-
zole/rifampin were included; ongoing AEs from the
olaparib-alone dosing period were not included. ClinicalVolume ] Number ]
L. Dirix et al.laboratory, vital signs and physical examination param-
eters were also evaluated.Statistical Analyses
The PK analysis set included all patients who
received an olaparib dose and provided evaluable PK
proﬁles in at least one treatment period (ie, olaparib or
olaparib plus itraconazole/rifampin). The safety anal-
ysis set (patients evaluable for safety) included all
patients who received at least one dose of olaparib
and for whom any post-dose data were available.
Safety data are presented descriptively.
In both studies, the primary PK outcome variables
of olaparib AUC, or AUC0–t if AUC was not
adequately estimable, and Cmax were statistically
analyzed to investigate the effect of itraconazole or
rifampin on the PK of olaparib. Following log trans-
formation, Cmax, AUC, and AUC0–t were analyzed
separately by mixed-effect analysis of variance
(ANOVA), ﬁtting terms for treatment as a ﬁxed effect
and patient as a random effect. Point estimates and
adjusted 90% conﬁdence intervals (CIs) for the differ-
ence between treatments (olaparib co-administered
with itraconazole or rifampin compared with olaparib
alone) for Cmax, AUC, and AUC0–t were constructed.
The point estimate and adjusted 90% CIs were then
exponentially back transformed to provide point and
CI estimates for the ratio of interest.
An analysis of tmax using the Wilcoxon signed rank
test and the Lehman median estimator of difference
(olaparib co-administered with itraconazole or rifam-
pin compared with olaparib alone) and 90% CIs are
also presented. All summaries and statistical analyses
were performed using SAS® version 8.1 or higher
(SAS Institute, Inc, Cary, North Carolina).Determination of Sample Size
In Study 7, recruitment of approximately 48 patients
was planned to ensure that 42 evaluable patients
completed the study. This sample size of 42 patients
was required to give 90% power to rule out a 20%
change in log-transformed AUC (and/or AUC0–t) and
Cmax of olaparib, ie, if the true effect of itraconazole on
olaparib exposure was minimal, the 90% CI treatment
ratio would be entirely within the bioequivalence range
of 0.80 to 1.25. Accordingly, no interaction of itraco-
nazole on the PK variables of olaparib was to be
concluded if the 2-sided 90% CIs for the treatment] 2016ratios of AUC (and/or AUC0–t) and Cmax fell entirely
within the bioequivalence range of 0.80–1.25.
In Study 8, recruitment of approximately
18 patients was planned to ensure that 16 evaluable
patients completed the study; 16 evaluable patients
were required to give 90% power to rule out a
halving of log-transformed AUC (and/or AUC0-t)
and Cmax of olaparib in the presence of rifampin,
indicated by a 90% CI for the treatment ratio entirely
above 0.5. Accordingly, no interaction between ola-
parib and rifampin was considered to have occurred if
the lower limit of the 90% CI for the treatment ratios
was greater than 0.5 (ie, o50% decrease in olaparib
AUC or Cmax in the presence of rifampin, compared
with olaparib alone).RESULTS
Patients
Table I shows the demographics and baseline
characteristics of patients in Study 7 and Study 8.
Between 2013 and 2014, 59 patients (17 male and 42
female) were assigned to Study 7, received at least one
dose of olaparib, and completed Part A; patients were
recruited from 11 centers in four countries. Between
2013 and 2014, 22 patients (4 male and 18 female)
were assigned to treatment in Part A and received at
least one dose of olaparib in Study 8; patients were
recruited from ﬁve centers in two countries.
In both studies, the majority of patients had an
ECOG performance status r1 and the most common
primary tumor type was ovarian (Table I).Pharmacokinetics
Study 7 (CYP3A4 Inhibition)
Of the 59 patients assigned to treatment, 56 and 53
patient proﬁles were evaluable for the olaparib alone
dosing period and the olaparib and itraconazole
dosing period, respectively. Three patients were ex-
cluded from both dosing periods due to a disallowed
surgical procedure (having previously had a gastric
band ﬁtted), baseline creatinine 450 mL/min, and
incorrect sample handling. Three additional patients
were excluded from the olaparib and itraconazole
dosing period due to a full itraconazole dose not being
administered, incorrect formulation of itraconazole
used (liquid rather than tablet), and PK samples not
provided. Although the protocol planned to enroll 48
evaluable patients, 11 additional patients were5
Table I. Summary of patient demographics and baseline clinical characteristics (safety analysis set).
Characteristic
Study 7 (Itraconazole)
(N ¼ 59)
Study 8 (Rifampin)
(N ¼ 22)
Median age (range), y 61.0 (34–82) 59.0 (31–79)
Sex, no. (%)
Male 17 (28.8) 4 (18.2)
Female 42 (71.2) 18 (81.8)
Race, no. (%)
White 55 (93.2) 22 (100)
Asian 2 (3.4) 0
Black/African American 1 (1.7) 0
Other 1 (1.7) 0
Weight, mean, kg (SD) 74.6 (19.4) 74.2 (14.0)
BMI, mean, kg/m2 (SD) 26.6 (5.7) 26.2 (4.4)
ECOG performance status, no. (%)*
0 25 (42.4) 7 (31.8)
1 32 (54.2) 11 (50.0)
2 2 (3.4) 3 (13.6)
Tumor type, no. (%)
Ovarian (including fallopian tube) 21 (35.6) 7 (31.8)
Colorectal 10 (16.9) 3 (13.6)
Pancreatic 7 (11.9) 0
Breast 3 (5.1) 5 (22.7)
Lung 3 (5.1) 0
Cervical 3 (5.1) 0
Peritoneal 2 (3.4) 0
Head and neck 2 (3.4) 0
Biliary tract 2 (3.4) 0
Uterine 2 (3.4) 0
Bladder (including urethra) 1 (1.7) 3 (13.6)
Other†,‡ 2 (3.4) 4 (18.2)
Disease classiﬁcation, no. (%)
Metastatic 53 (89.8) 20 (90.9)
Locally advanced 6 (10.2) 2 (9.1)
ECOG performance status and overall disease classiﬁcation were based on assessments at baseline. Primary tumor types are
based on assessments at diagnosis.
BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; SD = standard deviation.
*Data were missing for one patient in Study 8, who had metastatic well-differentiated (G1) colon cancer.
†Data were missing for one patient in Study 7.
‡Other primary tumor locations were central nervous system and biliopancreas in Study 7, and adrenal and prostate in 1
patient each and cancer of unknown primary in two patients in Study 8.
Clinical Therapeuticsrecruited and randomized to treatment to ensure that
sufﬁcient patient numbers were available for a later
part of the study (effect of olaparib on the QT interval
[to be reported separately]).6Following a single oral administration of olaparib
alone (100 mg tablet) in fasted conditions, the drug
appeared rapidly in plasma, with peak concentrations
typically observed 1 hour after dosing. FollowingVolume ] Number ]
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Figure 2. Geometric mean plasma concentration
of olaparib over time following a single
dose of olaparib alone or in combina-
tion with (A) itraconazole or (B)
rifampin.
L. Dirix et al.dosing in combination with itraconazole, median tmax
was slightly later (1.5 hours). Beyond the peak,
plasma concentrations in both treatment arms gener-
ally declined in a biphasic manner, remaining above
the limit of quantiﬁcation of the assay for up to 72
hours after dosing in the majority of patients where
sampling continued to that point (Figure 2).
Consistent with the increase in AUC, mean CL/F
and Vz/F were reduced when olaparib was dosed in
combination with itraconazole: 8.16 versus 3.05 L/h,
and 192 versus 75.1 L, respectively. However, the
mean t½ of olaparib was unchanged: 15.0 versus 15.6
hours, respectively, for olaparib alone versus olaparib
co-administered with itraconazole (Table II).
Co-administration of olaparib with itraconazole
resulted in a signiﬁcant increase in the relative bio-
availability of olaparib compared with olaparib ad-
ministered alone: Cmax treatment ratio, 1.42 (90% CI,
1.33–1.52); mean AUC treatment ratio, 2.70 (90%
CI, 2.44–2.97) (Table II). For individual patients, the
highest observed ratio for AUC was a seven-fold
increase.] 2016Cmax and AUC for itraconazole and hydroxyitracona-
zole determined after 5 days’ administration of itracona-
zole (200 mg once daily) are shown in Table III.
All patients in the olaparib plus itraconazole treat-
ment arm were shown to have been exposed to
itraconazole and its metabolite. Steady-state exposures
(Cmax and AUC) for itraconazole and hydroxyitraco-
nazole, determined after 5 days’ administration of
itraconazole (200 mg once daily), were of a similar
order of magnitude to the exposures reported in other
clinical PK studies using a similar dosing regimen
where signiﬁcant interactions have been demonstrated
(the mean itraconazole concentration previously re-
ported was 324 ng/mL).16 In six patients, however,
the plasma concentrations achieved for both
itraconazole and hydroxyitraconazole appeared low,
with the observed itraconazole Cmax o100 ng/mL
(range, 14.6–71.6 ng/mL). There was no clear
evidence that these patients were those in whom the
smallest effect was seen on olaparib, suggesting that
sufﬁcient itraconazole exposure to inhibit CYP3A4
had still been achieved in these patients.
Study 8 (CYP3A4 Induction)
All 22 patients had evaluable PK proﬁles, with no
important protocol deviations that impacted PK. The
olaparib plasma concentration–time proﬁles in the
absence and presence of rifampin are shown in
Figure 2B.
The rate of absorption of olaparib (300 mg) was
increased when administered in the presence of rifam-
pin, with a median tmax of 0.78 hours (range, 0.27–
5.95 hours), compared with olaparib administered
alone (1.49 hours; range, 0.57–3.05 hours)
(Table II). Co-administration of olaparib with rifam-
pin resulted in a statistically signiﬁcant decrease of
approximately 71% in the relative bioavailability of
olaparib (Cmax treatment ratio, 0.29 [90% CI, 0.24–
0.33]). Mean AUC was also reduced by 87% in the
presence of rifampin compared with olaparib admin-
istered alone (treatment ratio, 0.13 [90% CI, 0.11–
0.16]) (Table II).
Consistent with the decrease in AUC of olaparib,
mean CL/F increased 7.6-fold (6.36 vs 48.3 L/h) and
mean Vz/F increased 9.6-fold (112 vs 1076 L)
following dosing in the presence of rifampin (Table
II). However, there was no marked change in t½
compared with olaparib administered alone (13
hours for olaparib alone vs 15.8 hours in7
Table II. Pharmacokinetic parameters and relative bioavailability of single-dose olaparib alone or in combination with itraconazole or rifampin.
Data are expressed as geometric mean (geometric CV% [GCV]) for Cmax, AUC and AUC0-t; arithmetic mean (SD) for CL/F, Vz/F and t½;
and median (range) for tmax.
PK Parameter
Study 7 (Itraconazole) (N = 57) Study 8 (Rifampin) (N = 22)
Olaparib Alone
(100 mg)
Olaparib (100 mg) Plus
Itraconazole (200 mg)
Olaparib Alone
(300 mg)
Olaparib (300 mg) Plus
Rifampin (600 mg)
n 56 53 22 18
Cmax, mg/mL (GCV, %) 2.99 (48.2) 4.24 (37.7) 8.05 (24.3) 2.24 (53.4)
Cmax, mg/mL (GLS mean
ratio, 90% CI)
1.42 (1.33–1.52)* 0.29 (0.24–0.33)†
n 56 53 22 18
tmax, h (min–max) 1.03 (0.48–8.25) 1.50 (0.50–12.00) 1.49 (0.57–3.05) 0.78 (0.27–5.95)
n 53 49 21 17
AUC, mg/mL (GCV, %) 14.78 (75.4) 40.09 (72.1) 55.20 (67.4) 6.79 (46.4)
AUC, mg h/mL (GLS mean
ratio, 90% CI)
2.70 (2.44–2.97)* 0.13 (0.11–0.16)†
n 52 52 22 18
AUC0–t, mg/mL (GCV, %) 15.21 (76.0) 39.52 (68.8) 54.60 (63.8) 6.19 (60.2)
AUC0–t, mg h/mL (GLS mean
ratio, 90% CI)
2.66 (2.41–2.93)* 0.12 (0.10–0.15)†
n 53 49 21 17
t½, h (SD) 15.01 (8.23) 15.55 (6.44) 13.02 (4.16) 15.80 (9.55)
n 53 49 21 17
CL/F, L/h (SD) 8.16 (4.61) 3.05 (2.10) 6.36 (3.47) 48.3 (21.04)
n 53 49 21 17
Vz/F, L (SD) 191.8 (172.4) 75.14 (81.27) 112.1 (59.84) 1076 (868.8)
AUC, area under plasma concentration–time curve from time zero to inﬁnity; AUC0-t, area under plasma concentration–time curve from time zero to the last
measurable time point; CL/F, apparent clearance following oral administration; Cmax, maximum plasma concentration; CV, coefﬁcient of variation; GLS ¼ geometric
least squares; n ¼ number of patients with non-missing data; N ¼ PK analysis set (all patients who received at least one dose of study treatment and provided
evaluable PK proﬁles in at least one treatment period); t½, terminal half-life; tmax, time to maximal plasma concentration; Vz/F, apparent volume of distribution.
*Relative bioavailability: olaparib (100 mg) plus itraconazole (200 mg) versus olaparib (100 mg).
†Relative bioavailability: olaparib (300 mg) plus rifampin (600 mg) versus olaparib (300 mg).
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Table III. Pharmacokinetic parameters for itraconazole and hydroxyitraconazole obtained on the fifth day of
itraconazole dosing (Study 7). Data are expressed as geometric mean (geometric CV% [GCV]) for
Cmax and AUCtau; arithmetic mean (SD) for CL/F; and median (range) for Tmax.
PK Parameter Itraconazole (n ¼ 53) Hydroxyitraconazole (n ¼ 53)
Cmax, ng/mL (GCV, %) 245.5 (107.2) 313.3 (101.5)
tmax, h (min,max) 3.00 (1.00–12.00) 4.00 (0.00–8.03)
AUCtau, mg  h/mL (GCV, %) 2702 (108.1) 5341 (127.6)
CL/F, L/h (GCV, %) 74.02 (108.1) ND
AUCtau, area under plasma concentration–time curve for a dosing interval; CL/F, apparent clearance following oral
administration; Cmax, maximum plasma concentration; CV, coefﬁcient of variation; n ¼ number of patients with non-missing
data; ND ¼ not determined; tmax, time to maximal plasma concentration.
L. Dirix et al.combination with rifampin). Overall, mean plasma
concentrations of rifampin were generally consistent
on all study days, suggesting that steady-state ex-
posures had been maintained throughout the study
period (Figure 3A).
Following administration of rifampin (600 mg),
mean plasma 4β-hydroxycholesterol levels increased
approximately ﬁve-fold (from 55.2 nmol/L on day 5
to 316 nmol/L by day 17; ratio: 5.31 [90% CI, 4.68–
6.02]), indicating that CYP3A4 enzyme induction had
occurred (Figure 3B).100,000
10,000
1000
1000
100
10
5 6 7 8 9 10 11 12 13 14 15 16 17
Study Day
5 6 7 8 9 10 11 12 13 14 15 16 17
Study Day
G
eo
m
et
ri
c 
M
ea
n 
(S
D
)
C
on
ce
nt
ra
ti
on
 (
nm
ol
/L
)
G
eo
m
et
ri
c 
M
ea
n 
(S
D
)
C
on
ce
nt
ra
ti
on
 (
nm
ol
/L
)
Rifampin
4β-hydroxycholesterol
A
B
Figure 3. Geometric mean plasma concentration
of (A) rifampin over time (log scale)
and (B) 4β-hydroxycholesterol over
time (log scale).
] 2016Safety and Tolerability
Study 7 (CYP3A4 Inhibition)
In Study 7, a total of 42 (71.2%) patients reported
135 AEs. In the olaparib alone dosing period, nine
(15.3%) patients reported nine AEs considered by the
investigator as causally related to olaparib (nausea,
n ¼ 3; diarrhea, n ¼ 2; ﬂushing, n ¼ 1; headache,
n ¼ 1; rash, n ¼ 1; and rash erythematous, n ¼ 1). In
the olaparib plus itraconazole dosing period, 7
(11.9%) patients reported 11 AEs that were consid-
ered causally related to olaparib (constipation, n ¼ 2;
diarrhea, n ¼ 2; nausea, n ¼ 2; abdominal pain, n ¼
1; ascites, n ¼ 1; cough, n ¼ 1; headache, n ¼ 1; and
tinnitus, n ¼ 1). The majority of AEs were gastro-
intestinal in origin and of Common Terminology Criteria
for Adverse Events (CTCAE) grade 2 or lower. The AEs
reported by the greatest number of patients are shown in
Table IV.
In total, two (3.4%) and ﬁve (8.5%) patients
reported a CTCAE grade 3 AE in the olaparib alone
dosing period (diarrhea, nausea) and in the olaparib
plus itraconazole dosing period (anemia, fatigue, inter-
national normalized ratio increased nausea, urinary
tract obstruction, vomiting), respectively. Two patients
experienced SAEs of nausea (grade 2, grade 3), both in
the olaparib plus itraconazole dosing period, which
were considered by the investigator to be causally
related to olaparib. No AEs considered causally related
to olaparib treatment resulted in discontinuation of
olaparib.
One death was reported during the olaparib plus
itraconazole dosing period. The reported primary
cause of death was disease progression and was not
reported as an AE.9
Table IV. Adverse events experienced by 45% of patients overall in Study 7 or Study 8.*
AE, no. (%) of patients
Study 7 (Itraconazole) Study 8 (Rifampin)
Olaparib
(100 mg)
(n ¼ 59)
Olaparib (100 mg) Plus
Itraconazole (200 mg)
(n ¼ 59)
Olaparib
(300 mg)
(n ¼ 22)
Olaparib (300 mg) Plus
Rifampin (600 mg)
(n ¼ 22)
Patients with any AE 25 (42.4) 33 (55.9) 8 (36.4) 18 (81.8)
Diarrhea 4 (6.8) 4 (6.8) 1 (4.5) 3 (13.6)
Nausea 4 (6.8) 4 (6.8) 0 7 (31.8)
Constipation 2 (3.4) 6 (10.2) 1 (4.5) 2 (9.1)
Vomiting 2 (3.4) 4 (6.8) 0 6 (27.3)
Fatigue 2 (3.4) 5 (8.5) 0 2 (9.1)
Abdominal pain 1 (1.7) 2 (3.4) 1 (4.5) 3 (13.6)
Cough 1 (1.7) 3 (5.1) 0 0
Dyspepsia 1 (1.7) 2 (3.4) 0 1 (4.5)
Headache 1 (1.7) 5 (8.5) 1 (4.5) 3 (13.6)
Dyspnea 1 (1.7) 2 (3.4) 0 2 (9.1)
Hypokalemia 0 3 (5.1) 0 1 (4.5)
Back pain 0 3 (5.1) 0 0
Pain in extremity 0 2 (3.4) 0 2 (9.1)
Insomnia 0 1 (1.7) 0 2 (9.1)
Feces discolored 0 0 0 2 (9.1)
Malaise 0 0 0 2 (9.1)
Decreased appetite 0 0 1 (4.5) 3 (13.6)
Chromaturia 0 0 0 5 (22.7)
*AEs presented for olaparib alone and olaparib in combination should not be compared, as the combination data were
evaluated over a longer observation period and consist primarily of administration of the putative interacting drug alone.
Clinical TherapeuticsStudy 8 (CYP3A4 Induction)
In total, 19 (86.4%) patients experienced 90 AEs. Two
patients (9.1%) reported three AEs considered causally
related to olaparib (abdominal pain upper, diarrhea,
headache). In the olaparib plus rifampin dosing period,
ﬁve patients (22.7%) reported 14 AEs considered causally
related to olaparib (nausea, n ¼ 3; vomiting, n ¼ 3;
constipation, decreased appetite, diarrhea, gastrointestinal
hypermotility, hemoglobin urine present, malaise, stoma-
titis, urinary retention, all n ¼ 1). The most frequently
reported AEs are shown in Table IV. Chromaturia,
observed in ﬁve (22.7%) patients, is a known AE
associated with rifampin treatment.17
Two (9.1%) patients reported two CTCAE grade 3
AEs in the olaparib alone dosing period (decreased
appetite, lymphedema), and ﬁve (22.7%) patients
reported eight CTCAE grade 3 AEs in the olaparib
plus rifampin dosing period (abdominal pain, ascites,10convulsion, fatigue, headache, malaise, neutropenia,
and thrombocytopenia). None of the SAEs reported
were considered related to olaparib treatment and no
AEs resulted in discontinuation of olaparib.
There was one death reported during the olaparib
plus rifampin dosing period. The reported primary
cause of death was disease progression and was not
reported as an AE.DISCUSSION
Two Phase I, non-randomized, open-label studies
were conducted to investigate the effect of itracona-
zole, a potent CYP3A4 inhibitor, or rifampin, a potent
CYP3A4 inducer, on the PK proﬁle of olaparib
following a single dose of the tablet formulation.
Within the CYP superfamily, CYP3A is the most
important isoform since it is involved in theVolume ] Number ]
L. Dirix et al.metabolism of approximately half of known drugs, is
inducible by drugs and other small-molecule agents,
and is the major isoform expressed in the intestinal
epithelium, where it acts as a metabolic barrier to oral
absorption.18 Given that in vitro studies have shown
that the metabolism of olaparib is mediated by CYP
enzymes (McCormick & Swaisland, manuscript in
preparation for submission), predominantly CYP3A4/
5, the current Phase I studies were deemed important,
as PK interactions of olaparib, particularly with
agents that potently inhibit or induce CYP3A4,
could have clinical implications.
In Study 7, CYP3A4 was inhibited by administra-
tion of itraconazole 200 mg/d for 4 days before dosing
with a single 100 mg olaparib dose. This itraconazole
regimen resulted in steady-state exposures of itraco-
nazole and its metabolite, hydroxyitraconazole, con-
sistent with those of other clinical PK studies.16 Co-
administration of olaparib with itraconazole
signiﬁcantly increased olaparib mean plasma AUC
2.7-fold, while mean Cmax increased 1.4-fold, indicat-
ing that an interaction had occurred. Since the treat-
ment ratios and 90% CIs for both Cmax and AUC
were outside the predeﬁned bioequivalence range
(0.80–1.25), these ﬁndings show that itraconazole
has a statistically signiﬁcant and potentially clinically
relevant effect on olaparib. Although the increase in
olaparib exposure observed with concomitant itraco-
nazole administration was not large compared with
the effect of itraconazole reported for other CYP3A4
substrates such as midazolam (where eight-fold
increases in AUC have been observed),19 it was
statistically signiﬁcant. The clinical consequences of
an increase in olaparib exposure with concomitant
administration of a CYP3A4 inhibitor such as
itraconazole are unclear. There was no difference in
t½ of olaparib when dosed in combination with
itraconazole, but both CL/F and Vz/F were
decreased, reﬂecting the increased exposure to
olaparib. The unchanged elimination t½ of olaparib
despite the decreased clearance and volume of
distribution suggests that itraconazole may
predominantly affect olaparib exposure by altering
its bioavailability, possibly through inhibition of
transporter-mediated processes in the gut, resulting
in a change in the extent of olaparib absorption.
Preclinical data have shown that olaparib is a
substrate for P-glycoprotein (McCormick & Swaisland,
manuscript in preparation for submission), and] 2016itraconazole is an inhibitor of this transporter system,
as well as of CYP3A4-mediated metabolism.20 Given
the increased exposure to olaparib when co-
administered with the CYP3A4 inhibitor itraconazole
observed in the current study, it is recommended that
potent CYP3A4 enzyme inhibitors (eg, itraconazole,
telithromycin, clarithromycin, ketoconazole, voricona-
zole, nefazodone, posaconazole, ritinovir, lopinavir,
indinavir, saquinavir, nelﬁnavir, boceprevir, telaprevir)
should be avoided during olaparib treatment.
In Study 8, CYP3A4 was induced by administra-
tion of rifampin 600 mg/d for 9 days before dosing
with a single 300 mg olaparib dose (2  150 mg
tablets). Exposure to rifampin 600 mg was of a similar
magnitude to that reported in other controlled clinical
PK studies using a similar dosing regimen where
signiﬁcant drug–drug interactions have been demon-
strated.21–23 CYP3A4 enzyme induction by rifampin
was shown in all patients by a consistent increase in
the endogenous biomarker 4β-hydroxycholesterol.
Co-administration of olaparib with rifampin signiﬁ-
cantly reduced olaparib mean plasma AUC by ap-
proximately 87%. There was also a signiﬁcant
decrease of 71% in the Cmax of olaparib. The treat-
ment ratio and 90% CI for AUC and Cmax wereo0.5
(ie, greater than halving of the exposure), indicating a
statistically signiﬁcant interaction between olaparib
and rifampin.
As with Study 7, given the lack of any apparent
change in elimination t½ of olaparib, the changes in
olaparib exposure may reﬂect a change in the extent
of drug absorption, in this case, a decrease in drug
absorption that is possibly transporter protein medi-
ated (P-glycoprotein). The observed increase in
plasma clearance is consistent with induction of
CYP3A4-mediated metabolism. Together with the
possible induction of P-glycoprotein efﬂux and con-
sequently reduced oral bioavailability, the increased
plasma clearance would explain the observed reduc-
tion in AUC and Cmax. Reduced exposure to
olaparib when taken with CYP3A4 enzyme inducers
could potentially reduce olaparib efﬁcacy. It is there-
fore recommended that potent CYP3A4 enzyme
inducers (eg, phenytoin, rifampin, carbamazepine,
St. John’s wort) should be avoided during olaparib
treatment.
A limitation of these studies is that the majority of
patients were Caucasian. It is known that there are
ethnic differences because of genetic variability in11
Clinical Therapeuticsdrug-metabolizing enzymes such as CYP.24
The recommendation from this study that
CYP3A4 inhibitors or inducers should be avoided
during olaparib treatment is relevant for all
ethnicities.
Across both studies, the number and type of AEs
reported were in line with what would be expected for
this patient population and the known safety proﬁle
for olaparib.7,25–28 The majority of AEs reported were
of mild or moderate severity. Olaparib showed an
acceptable tolerability proﬁle, and no new safety
ﬁndings were observed. Phase III trials of olaparib
tablet formulation in patients with ovarian, breast,
pancreatic, and gastric cancers are ongoing.29–35CONCLUSIONS
In these Phase I studies, exposure to olaparib as
assessed by AUC and Cmax was increased when a
single 100 mg dose was given in combination with the
CYP3A4 inhibitor itraconazole. Conversely, olaparib
exposure was decreased when a single 300-mg dose
was given in combination with the CYP3A4 inducer
rifampin. Based on these ﬁndings, it is recommended
that potent CYP3A4 enzyme inhibitors and inducers
should be avoided during olaparib treatment. No
clinically relevant safety signals were observed when
a single dose of olaparib was administered in combi-
nation with itraconazole or rifampin. The safety data
for olaparib tablets were consistent with the known
safety proﬁle of this drug.ACKNOWLEDGMENTS
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